par Blanc, Jeremy
;Carnot, Aurélien;Barthélémy, Philippe;Casert, Vinciane;Sautois, Brieuc;Van den Brande, Jan;Vanhaudenarde, Vincent;Staudacher, Lionel;Seront, Emmanuel;Debien, Veronique;Ameye, Lieveke;Kotecki, Nuria;Rothé, Françoise
;Rorive, Sandrine
;Fantoni, Jean Christophe;Tricard, Thibault;Roumeguère, Thierry;Awada, Ahmad;Martinez Chanza, Nieves
Référence Journal for ImmunoTherapy of Cancer, 13, 5
Publication Publié, 2025-05-01



Référence Journal for ImmunoTherapy of Cancer, 13, 5
Publication Publié, 2025-05-01
Article révisé par les pairs
Résumé : | Immunotherapy is becoming a standard of care for non-metastatic muscle-invasive bladder cancer (MIBC). The optimal chemotherapy partner for chemo-immunotherapy combinations remains unknown. We evaluated the efficacy and safety of neoadjuvant avelumab-based regimens in patients with MIBC. |